Articles Tagged With:
-
If they’re so difficult to reprocess, why are duodenoscopes approved for surgery?
With all of the difficulties in cleaning duodenoscopes, and the potential for outbreaks of carbapenem-resistant Enterobacteriaceae, some outpatient surgery managers are questioning why these scopes are approved by the Food and Drug Administration. However, the benefits outweigh the risks, some sources say.
-
Culturing protocols devised for duodenoscopes to prevent CRE
Responding to a series of outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) linked to duodenoscopes, the Centers for Disease Control and Prevention has developed an interim protocol for culturing the devices before use to create a greater margin of safety for patients. But as others have noted, the approach is not foolproof and could be costly if facilities determine that they must purchase more scopes to adopt the protocol.
-
Acute Shoulder Injury
MONOGRAPH: Musculoskeletal injuries or pain complaints comprise a large portion of visits to EDs every year.
-
FDA Greenlights Biosimilars
In one of the most important decisions of the past 5 years, the FDA has given the greenlight to the first biosimilar drug with the approval of Sandoz’s filgrastim-sndz, a copy of Amgen’s multibillion dollar drug filgrastim (Neupogen). Biosimilars are drugs that are derived from living organisms and thus cannot be exact copies of the original compounds. They are different from generics in this respect. But the FDA has agreed to approve biologic copies that are “highly similar to another, already FDA-approved biologic (known as the reference product).”
-
FDA Actions
The FDA has approved afibercept for the treatment of diabetic retinopathy in patients with diabetic macular edema.
-
FDA Greenlights Biosimilars
In one of the most important decisions of the past 5 years, the FDA has given the greenlight to the first biosimilar drug with the approval of Sandoz’s filgrastim-sndz, a copy of Amgen’s multibillion dollar drug filgrastim (Neupogen).
-
Might Long-term Dual Antiplatelet Therapy Be Better? Not
Risk reduction provided by dual antiplatelet therapy (DAT) in the short-term interval (3-12 months) after coronary stenting is well established, and published guidelines provide consistent advice about appropriate duration of such therapy.
-
Dual Add-on Therapy for Type 2 Diabetes When Metformin is Not Enough
The current (2015) American Diabetes Association guidance for progression of treatment when A1c goals are not attained with metformin implies stepwise initiation of additional monotherapies.
-
Chronobiology and Insulin Glargine
The “indication” labeling for insulin glargine (Lantus) simply says, “Administer subcutaneously once daily at any time of day, but at the same time every day.”
-
Bipolar Disorder is Associated with New-onset CVD
Although perhaps not widely recognized, bipolar disorder (BPD) is associated with an excessive risk of cardiovascular disease (CVD). Not only is CVD more prevalent, but it occurs as much as a decade earlier than comparators without BPD.